Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Capital Expenditures (2023 - 2025)

Camp4 Therapeutics' Capital Expenditures history spans 3 years, with the latest figure at -$76000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 128.9% year-over-year to -$76000.0; the TTM value through Dec 2025 reached $203000.0, down 53.97%, while the annual FY2025 figure was $203000.0, 53.97% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$76000.0 at Camp4 Therapeutics, down from $279000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $279000.0 in Q1 2025 and bottomed at -$76000.0 in Q4 2025.
  • The 3-year median for Capital Expenditures is $89000.0 (2024), against an average of $100000.0.
  • The largest annual shift saw Capital Expenditures skyrocketed 697.73% in 2024 before it crashed 128.9% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at -$44000.0 in 2023, then surged by 697.73% to $263000.0 in 2024, then plummeted by 128.9% to -$76000.0 in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Capital Expenditures are -$76000.0 (Q4 2025), $279000.0 (Q1 2025), and $263000.0 (Q4 2024).